Notice: This company has been marked as potentially delisted and may not be actively trading. Tenzing Acquisition (TZAC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends TZAC vs. LSB, BTAI, CVKD, GDTC, LSTA, TPST, CMMB, AEON, XCUR, and COCPShould you be buying Tenzing Acquisition stock or one of its competitors? The main competitors of Tenzing Acquisition include Lakeshore Biopharma (LSB), BioXcel Therapeutics (BTAI), Cadrenal Therapeutics (CVKD), CytoMed Therapeutics (GDTC), Lisata Therapeutics (LSTA), Tempest Therapeutics (TPST), Chemomab Therapeutics (CMMB), AEON Biopharma (AEON), Exicure (XCUR), and Cocrystal Pharma (COCP). Tenzing Acquisition vs. Lakeshore Biopharma BioXcel Therapeutics Cadrenal Therapeutics CytoMed Therapeutics Lisata Therapeutics Tempest Therapeutics Chemomab Therapeutics AEON Biopharma Exicure Cocrystal Pharma Tenzing Acquisition (NASDAQ:TZAC) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Is TZAC or LSB more profitable? Lakeshore Biopharma's return on equity of 0.00% beat Tenzing Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Tenzing AcquisitionN/A -13.32% -1.36% Lakeshore Biopharma N/A N/A N/A Which has preferable earnings & valuation, TZAC or LSB? Tenzing Acquisition has higher earnings, but lower revenue than Lakeshore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenzing AcquisitionN/AN/A$620KN/AN/ALakeshore Biopharma$80.82M0.31-$61.09MN/AN/A Do insiders & institutionals believe in TZAC or LSB? 60.9% of Tenzing Acquisition shares are owned by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are owned by institutional investors. 37.5% of Tenzing Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in TZAC or LSB? Tenzing Acquisition and Lakeshore Biopharma both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformTenzing AcquisitionN/AN/ALakeshore BiopharmaN/AN/A Which has more volatility and risk, TZAC or LSB? Tenzing Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Does the media favor TZAC or LSB? In the previous week, Tenzing Acquisition's average media sentiment score of 0.00 equaled Lakeshore Biopharma'saverage media sentiment score. Company Overall Sentiment Tenzing Acquisition Neutral Lakeshore Biopharma Neutral SummaryLakeshore Biopharma beats Tenzing Acquisition on 4 of the 7 factors compared between the two stocks. Ad Insiders Exposed917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Tenzing Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TZAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TZAC vs. The Competition Export to ExcelMetricTenzing AcquisitionPharmaceutical Preparations Industry SectorNASDAQ ExchangeMarket Cap$6.23M$6.53B$1.97B$8.84BDividend YieldN/A8.11%15.23%4.07%P/E RatioN/A5.5010.9414.22Price / SalesN/A375.025,384.0488.42Price / Cash143.1052.59112.4936.27Price / Book1.2410.271.186.37Net Income$620,000.00$153.22M-$688.09M$225.56M Tenzing Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TZACTenzing AcquisitionN/A$1.22-3.2%N/A-71.1%$6.23MN/A0.00N/AHigh Trading VolumeLSBLakeshore Biopharma0.2075 of 5 stars$2.67+1.9%N/AN/A$24.86M$80.82M0.00773BTAIBioXcel Therapeutics4.5363 of 5 stars$0.58-2.2%$5.00+769.6%-84.6%$24.58M$1.38M0.0090Gap DownCVKDCadrenal Therapeutics1.683 of 5 stars$14.53+0.2%$18.00+23.9%N/A$24.12MN/A0.004GDTCCytoMed Therapeutics1.8866 of 5 stars$2.20-0.5%$5.00+127.3%-40.3%$24.07MN/A0.00N/ALSTALisata Therapeutics3.3126 of 5 stars$2.85-2.7%$15.00+426.3%+33.6%$23.91MN/A-1.1730Analyst ForecastTPSTTempest Therapeutics2.265 of 5 stars$0.91+1.0%$20.00+2,104.8%-76.2%$22.87MN/A-0.5920Analyst RevisionCMMBChemomab Therapeutics2.8753 of 5 stars$1.56-4.9%$7.33+370.1%+228.0%$22.40MN/A0.0020AEONAEON Biopharma3.5986 of 5 stars$0.57+1.2%$5.00+776.9%-88.5%$22.31MN/A0.005Positive NewsXCURExicure1.8055 of 5 stars$10.27-8.2%N/A+1,914.4%$22.29M$28.83M-4.9550News CoverageGap DownTrading HaltedCOCPCocrystal Pharma3.0393 of 5 stars$2.16+4.9%$7.00+224.1%+25.6%$21.97MN/A-1.1710 Related Companies and Tools Related Companies Lakeshore Biopharma Competitors BioXcel Therapeutics Competitors Cadrenal Therapeutics Competitors CytoMed Therapeutics Competitors Lisata Therapeutics Competitors Tempest Therapeutics Competitors Chemomab Therapeutics Competitors AEON Biopharma Competitors Exicure Competitors Cocrystal Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TZAC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenzing Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenzing Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TZAC Stock Alerts